BRAF Biomarkers News and reporting on BRAF biomarkers. Oct 4, 2022 Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients Premium Sep 20, 2022 Elicio Receives $2.8M Grant for Cancer Vaccine Development Sep 13, 2022 METiS Gets Exclusive License to Voronoi's Pan-RAF Inhibitor Aug 23, 2022 Erasca, MD Anderson Cancer Center Partner to Study ERK, SHP2 Inhibitors Jul 12, 2022 NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling Jul 7, 2022 CancerTYPE ID Study Underscores Value of Knowing Tissue of Origin Amid Tissue-Agnostic Approvals Premium Jun 23, 2022 MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients Premium Jun 23, 2022 Novartis Nets Tumor-Agnostic Approval for Tafinlar-Mekinist Combo Jun 14, 2022 Day One Bio's Tovorafenib Market Prospects Look Promising Based on Pediatric Glioma Trial Data Premium Jun 6, 2022 With ASCO Data, Novartis' Tafinlar-Mekinist Heads Toward FDA for BRAF-Mutant Pediatric Brain Cancer Premium Apr 26, 2022 Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce Apr 11, 2022 As NCI-MATCH Winds Down, Cancer Research Community Takes Stock of Lessons Learned Premium Mar 17, 2022 NCI-MATCH Umbrella Trial Adds Arm for LAG-3 Expressing, Mismatch Repair Deficient Cancers Mar 10, 2022 Erasca, Eli Lilly Partner to Study ERAS-007, Erbitux in BRAF V600E-Mutant Colorectal Cancer Feb 11, 2022 Seattle Cancer Care Alliance Aims to Improve Molecular Profiling Access for Thyroid Cancer Patients Premium Feb 4, 2022 CHOP Researchers Find Gene Fusions are Harbingers of Aggressive Disease in Pediatric Thyroid Cancer Premium Jan 4, 2022 MSK, Amgen Explore Lumakras Combination Regimens to Overcome KRAS Inhibitor Resistance Premium Dec 9, 2021 SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance Nov 24, 2021 Opdivo-Yervoy Before Tafinlar-Mekinist Provides Optimal Benefit to BRAF-Mutant Melanoma Patients Premium Nov 22, 2021 Day One Biopharmaceuticals Begins Phase II Trial in RAF-Altered Solid Tumors Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
